Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

President’s Budget Paves The Critical Path With $6 Mil. Request

Executive Summary

FDA requests $6 mil. and six FTEs for its Critical Path initiative in fiscal 2007, marking the first time funding has been proposed for the program

You may also be interested in...



“Critical Path” Is On The Road Forward; FDA Reports Industry Activity Is High

The Critical Path Initiative is entering 2007 with growing momentum, bolstered by a new, tailored agency infrastructure and increased industry awareness of FDA's initiative to spur drug development

“Critical Path” Is On The Road Forward; FDA Reports Industry Activity Is High

The Critical Path Initiative is entering 2007 with growing momentum, bolstered by a new, tailored agency infrastructure and increased industry awareness of FDA's initiative to spur drug development

Generic review appropriations

The Senate Agriculture Appropriations bill reported by the full appropriations committee June 22 includes $10 mil. more for generic drug reviews than in the president's request. It exceeds the House version by $5 mil. The committee requests that FDA submit a report on any changes that have been made to the generic drug approval process. If the funding survives conference, it could end recently reignited debate over generic drug user fees (1"The Pink Sheet" Feb. 27, 2006, p. 8). The Senate bill fully funds the president's request for an additional $6 mil. for the Critical Path initiative and $4 mil. for drug safety activities (2"The Pink Sheet" Feb. 13, 2006, p. 9)...

Related Content

UsernamePublicRestriction

Register

PS046868

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel